Turning a patient's own blood into the dopamine neurons that Parkinson's disease takes away - and putting them back.
PHOTO: The company logo, photographed doing what logos do best - standing still while the science does the moving.
The Scene, June 2026
In a small clinical trial run inside Mass General Brigham, a Parkinson's patient sat for a routine DaT scan - the imaging test that maps how much dopamine machinery is left in the brain. On the treated side of the putamen, the signal had climbed more than five-fold in six months. On the untreated side, it kept sliding the way Parkinson's always makes it slide.
That asymmetry is the whole story of Oryon Cell Therapies. One half of a brain getting measurably better while the other half declines on schedule. It is the difference between managing a disease and reversing a piece of it - and in March 2026, it was enough to bring a quiet, six-year-old company out of stealth with $21 million and a CEO who used to run a public neurology company.
The Problem They Saw
Parkinson's disease does something cruel and specific. It kills a particular population of dopamine-producing neurons - the A9 cells deep in the brain - and as they disappear, so does smooth movement. Tremor arrives. Steps get shorter. Faces stop moving. The standard treatment, levodopa, tops up the missing dopamine chemically, which works beautifully until it doesn't, and the dose creeps up while the disease keeps subtracting.
For decades the obvious counter-move has been just as simple to say and brutally hard to do: if the problem is missing neurons, put neurons back. Cell transplant experiments for Parkinson's go back to the 1980s. The biology was promising and the execution was a minefield - inconsistent cells, immune rejection, surgical risk, and the awkward fact that the brain is not a place you want to learn on the job.
So the field mostly settled for management. Pills, deep-brain stimulation, more pills. Useful, undramatic, and quietly accepting that decline was the only direction available. Oryon's founders never quite accepted it.
The Founders' Bet
Oryon was founded in 2020 out of the Neuroregeneration Research Institute at McLean Hospital, a Harvard Medical School affiliate. The scientific lineage matters here. Ole Isacson, the institute's founding director, has spent his career on neuron replacement. He co-founded the company with Nikola Kojic, M.D., Ph.D., and the science draws on work alongside Penelope Hallett, the institute's co-director. This is not a team that discovered Parkinson's cell therapy last year - it is a team that has been waiting for the tools to catch up to the idea.
The bet has two parts. First: make the replacement neurons from the patient's own blood. Oryon reprograms a patient's blood cells into induced pluripotent stem cells, then differentiates those into fully developed A9 dopamine neurons. Because the cells are the patient's own - autologous - there is no donor mismatch and, critically, no need for lifelong immune suppression. That single design choice removes one of the heaviest burdens that has haunted brain-cell transplants.
Second: implant mature neurons, not progenitors, and treat one hemisphere at a time. Rather than seeding immature precursor cells and hoping they grow up correctly inside the brain, Oryon delivers fully differentiated dopamine neurons - cells already trained to do the job. And it starts unilaterally, treating a single side of the putamen, a more conservative footprint than the bilateral approaches several competitors use.
The Product
Oryon's lead program is an autologous dopaminergic neuron replacement therapy. The pipeline of a single dose reads almost like a manufacturing line for the nervous system: draw the patient's blood, reprogram those cells into induced pluripotent stem cells, coax them down a proprietary path into A9 dopamine neurons, quality-check the result, and then a surgeon implants them into the putamen - the brain region where the missing dopamine signal needs to land.
The point is restoration, not chemistry. Levodopa floods the brain with dopamine on a dosing schedule. Implanted neurons are supposed to sit in the circuit and produce it the way the original cells did, on the brain's own terms. If it works at scale, the goal is fewer pills, steadier movement, and a slope that bends back up instead of only down.
The same platform is the company's longer game. The machinery for turning a patient's blood into a specific neuron type is, in principle, not limited to dopamine cells or to Parkinson's. Oryon describes its ambition as neuron replacement for neurodegenerative disorders broadly - Parkinson's is the proof, not the ceiling.
The Proof
Early-stage data deserves early-stage skepticism, and Parkinson's is famously vulnerable to placebo - people feel better when they believe a treatment is working. That is exactly why Oryon leans on imaging. A scan does not get excited. The Phase 1b/2a results, presented at the AD/PD 2026 conference, paired motor improvements with neuroimaging that the medication-only path does not produce.
Participants showed improvements in core Parkinson's motor symptoms - bradykinesia, rigidity, and gait - along with functional measures like the Timed Up and Go mobility test. Several reduced their levodopa equivalent daily dose, a real-world sign that the brain needed less chemical top-up. And the imaging told the most pointed story: in one patient, the DaT signal in the treated putamen rose more than five-fold at six months versus baseline, while the untreated side declined.
DaT imaging signal, relative scale (baseline = 100). Illustrative of reported direction; treated vs. untreated hemisphere.
The treated half climbed. The untreated half did what Parkinson's does. Same brain, same six months.
The credibility is not only in the cells. Oryon's clinical work runs through Mass General Brigham, including Brigham & Women's Hospital, with the founding science anchored at McLean's Neuroregeneration Research Institute. And the new money - $21 million from Neuro.VC and Byers Capital on top of earlier equity and grants - is earmarked for the unglamorous, decisive work: finishing the Phase 1b/2a trial, scaling manufacturing, and building toward a Phase 3.
The Mission
Oryon's stated mission is to develop autologous neuron replacement medicines for Parkinson's and other neurodegenerative disorders. Strip away the jargon and it is a fairly stubborn idea: that lost neurons can be replaced with a patient's own reprogrammed cells, and that the right goal is functional restoration rather than slower decline.
That framing puts Oryon in a crowded but distinct neighborhood. Aspen Neuroscience is also chasing autologous iPSC therapy and moving toward Phase 3. Bayer, through its cell-therapy work, is advancing a late-stage allogeneic - donor-derived - approach. Hope Biosciences has its own data. Oryon's differentiators are the design choices it keeps repeating: mature A9 neurons instead of progenitors, the patient's own cells instead of a donor's, and a unilateral start instead of treating both sides at once.
Why It Matters Tomorrow
Parkinson's affects millions of people, and the population skews older every year. A therapy that restores dopamine function from a patient's own cells - without a donor, without immune suppression, with imaging to prove it - would not be a tweak to the standard of care. It would be a different category of answer.
The cautions are real. This is a small trial. One striking scan is one scan. Manufacturing a custom batch of neurons for every patient is expensive and slow, and the road from Phase 1b/2a to an approved Phase 3 product is long and littered with companies that had promising early data. Oryon knows the history better than most - its founders helped write part of it.
Back to the Scan
Return to that DaT scan. For forty years, the picture of a Parkinson's brain over time has had one honest direction: down. Oryon's contribution, for now, is a single image where one half went the other way - not by accident, not by placebo, but because someone put working dopamine neurons back where the disease had taken them out.
The next question is obvious and Oryon is funded to ask it: light up the other hemisphere, in more patients, in a bigger trial, and see if the picture holds. If it does, the scan stops being a remarkable exception and starts being the plan.
Worth Knowing